1 Tepper R, "Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients" 64 : 386-391, 1997
2 Le Donne M, "Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings" 26 : 623-626, 2005
3 Markovitch O, "The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients" 95 : 456-462, 2004
4 Senkus-Konefka E, "The effects of tamoxifen on the female genital tract" 30 : 291-301, 2004
5 Mourits MJ, "The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium" 55 : 514-519, 2002
6 Dibi RP, "Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer" 16 : 293-300, 2009
7 Mourits MJ, "Tamoxifen treatment and gynecologic side effects: a review" 97 : 855-866, 2001
8 Qureshi A, "Spectrum of tamoxifen associated endometrial pathology in breast cancer patients" 59 : 249-250, 2009
9 Cohen I, "Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen" 92 : 1151-1155, 2001
10 ACOG committee opinion, "No. 336: Tamoxifen and uterine cancer. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice" 107 : 1475-1478, 2006
1 Tepper R, "Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients" 64 : 386-391, 1997
2 Le Donne M, "Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings" 26 : 623-626, 2005
3 Markovitch O, "The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients" 95 : 456-462, 2004
4 Senkus-Konefka E, "The effects of tamoxifen on the female genital tract" 30 : 291-301, 2004
5 Mourits MJ, "The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium" 55 : 514-519, 2002
6 Dibi RP, "Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer" 16 : 293-300, 2009
7 Mourits MJ, "Tamoxifen treatment and gynecologic side effects: a review" 97 : 855-866, 2001
8 Qureshi A, "Spectrum of tamoxifen associated endometrial pathology in breast cancer patients" 59 : 249-250, 2009
9 Cohen I, "Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen" 92 : 1151-1155, 2001
10 ACOG committee opinion, "No. 336: Tamoxifen and uterine cancer. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice" 107 : 1475-1478, 2006
11 Al-Brahim N, "Metastatic breast lobular carcinoma to tamoxifen-associated endometrial polyp: case report and literature review" 9 : 166-168, 2005
12 Cohen I, "Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients" 75 : 136-141, 1999
13 Goncalves MA, "Hysteroscopic evaluation of the endometrium of post-menopausal patients with breast cancer before and after tamoxifen use" 66 : 273-279, 1999
14 Neven P, "Guidelines for monitoring patients taking tamoxifen treatment" 22 : 1-11, 2000
15 Lin MC, "Endometrial thickness after menopause: effect of hormone replacement" 180 : 427-432, 1991
16 Antunes A Jr, "Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy" 57 : 415-421, 2007
17 Cohen I, "Endometrial pathologies associated with postmenopausal tamoxifen treatment" 94 : 256-266, 2004
18 Maugeri G, "Endometrial lesions after tamoxifen therapy in breast cancer women" 7 : 240-244, 2001
19 Gregoriou O, "Clinical parameters linked with malignancy in endometrial polyps" 12 : 454-458, 2009